Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? (CROSBI ID 720510)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Rnjak, Dina ; Ravlić, Sanda ; Šola, Ana-Marija ; Halassy, Beata ; Šemnički , Joško ; Šuperba , Martina ; Hećimović , Ana ; Kurolt , Ivan- Christian ; Kurtović , Tihana ; Mačak Šafranko , Željka et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?. 2021. str. 46-46

Podaci o odgovornosti

Rnjak, Dina ; Ravlić, Sanda ; Šola, Ana-Marija ; Halassy, Beata ; Šemnički , Joško ; Šuperba , Martina ; Hećimović , Ana ; Kurolt , Ivan- Christian ; Kurtović , Tihana ; Mačak Šafranko , Željka ; Zenić , Lucija ; Polančec , Denis ; Bendelja , Krešo ; Mušlin , Tatjana ; Jukić , Irena ; Vuk , Tomislav ; Artuković , Marinko

engleski

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 in a patient with a history of nasopharyngeal diffuse large B- cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV-2 neutralizing antibodies in a patient plasma during the course of therapy. Besides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human), were quantified in a time- dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations. The phases of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Therapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 into a partly manageable chronic disease.

passive antibody therapy ; convalescent plasma ; COVID-19 ; SARS-CoV-2 ; wild-type virus neutralization assay

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

46-46.

2021.

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

Annual meeting of the Croatian Immunological Society 2021

poster

23.09.2021-25.09.2021

Trogir, Hrvatska

Povezanost rada

Biologija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Kliničke medicinske znanosti, Temeljne medicinske znanosti